ChemoCentryx, Inc.

Informe acción NasdaqGS:CCXI

Capitalización de mercado: US$3.7b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ChemoCentryx Crecimiento futuro

Future controles de criterios 5/6

Información clave

69.1%

Tasa de crecimiento de los beneficios

91.90%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs25.4%
Tasa de crecimiento de los ingresos85.1%
Rentabilidad financiera futura6.59%
Cobertura de analistas

Low

Última actualizaciónn/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Seeking Alpha • Oct 18

ChemoCentryx shareholders approve $4.7B merger with Amgen

ChemoCentryx shareholders have overwhelmingly approved Amgen's (NASDAQ:AMGN) $3.7B acquisition of the company. With the acquisition, Amgen (AMGN) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare diseases characterized by destruction and inflammation of small vessels. NASDAQ said ChemoCentryx's (NASDAQ:CCXI) anticipated last day of trading will be Oct. 19.
Seeking Alpha • Aug 09

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

ChemoCentryx press release (NASDAQ:CCXI): Q2 GAAP EPS of -$0.44 misses by $0.03. Revenue of $11.76M (+553.3% Y/Y) misses by $9.89M. On August 3, 2022, the company entered into merger deal with Amgen under which Amgen will acquire the Company for $52.00 per share in cash, representing an enterprise value of approximately $3.7 billion. The transaction is subject to the company's stockholder approval, regulatory approvals and other customary closing conditions, and is expected to close in the fourth quarter of 2022. Also Read: Amgen posts 2Q beat, trims earnings guidance; new drugs outperform
Seeking Alpha • Jun 21

ChemoCentryx: Revisiting The Investment Case

Today, we revisit a biopharma concern called ChemoCentryx for the first time since late in 2021. The company is in the initial rollout of its primary product TAVNEOS, which is approved for one indication and in development for three other diseases. ChemoCentryx has a solid balance sheet and analyst firms are modeling explosive revenue growth ahead for the company. An investment analysis follows in the paragraphs below.
Artículo de análisis • Jun 06

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Mar 03

ChemoCentryx: Good Post-Approval Performance, But Needs More Time

CCXI got its first approval last October. Revenue and patient uptake has been good. A few more quarters will be needed to assess the company properly.
Artículo de análisis • Feb 11

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Artículo de análisis • Jan 21

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Celebrations may be in order for ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders, with the analysts delivering a...
Seeking Alpha • Dec 15

Checking In On ChemoCentryx

Today, we put mid-cap biopharma name ChemoCentryx in the spotlight. The company's primary compound was recently approved for the treatment of vasculitis. A full investment analysis is presented in the paragraphs below.
Artículo de análisis • Oct 09

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Sep 29

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

ChemoCentryx is developing Avacopan - a C5 complement receptor inhibitor - for several autoimmune conditions. The company has an upcoming PDUFA date for Avacopan in ANCA vasculitis - the FDA will make its decision on whether to approve the drug on October 7th. The original date was July 2021 but the decision was delayed after ChemoCentryx provided additional data. An FDA Adcom was split over an approval verdict in May. ChemoCentryx stock traded at $68 prior to the Adcom and PDUFA date delay, based on a $1.9bn peak sales potential. Today, shares trade at $20. Avacopan won approval in Japan this week - an encouraging sign - but I suspect the FDA may reject the therapy this time around, and that ChemoCentryx market valuation will fall further as a result - it will be a marginal decision.
Seeking Alpha • Aug 24

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021. Regulatory review is ongoing with the PDUFA extended to Oct. 6, 2021, in response to new filing by CCXI which the FDA designated as a major amendment to the NDA. The good news is that CCXI has not been issued the dreaded complete response letter. The outcome of the PDUFA is dependent on a satisfactory rebuttal to the Adcom questions and comments. Read on for details on the potential regulatory review outcome.
Artículo de análisis • Aug 11

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

The latest analyst coverage could presage a bad day for ChemoCentryx, Inc. ( NASDAQ:CCXI ), with the analysts making...
Seeking Alpha • Jul 25

ChemoCentryx: CRL Less Likely

In my previous coverage, I said many analysts including myself thought a CRL was likely for avacopan. However, the FDA has accepted an amendment to the NDA and given an October 7 PDUFA date. There are reasons to think the outcome may be positive.
Artículo de análisis • Jul 11

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Today we will run through one way of estimating the intrinsic value of ChemoCentryx, Inc. ( NASDAQ:CCXI ) by estimating...
Artículo de análisis • Jun 15

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Artículo de análisis • Mar 03

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

We feel now is a pretty good time to analyse ChemoCentryx, Inc.'s ( NASDAQ:CCXI ) business as it appears the company...
Artículo de análisis • Feb 04

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Artículo de análisis • Dec 31

Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Some ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders may be a little concerned to see that the Independent Director...
Artículo de análisis • Dec 23

Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Today is shaping up negative for ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders, with the analysts delivering a...
Artículo de análisis • Dec 13

Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Investing can be hard but the potential fo an individual stock to pay off big time inspires us. But when you hold the...
Artículo de análisis • Nov 22

Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

In this article we are going to estimate the intrinsic value of ChemoCentryx, Inc. (NASDAQ:CCXI) by taking the...

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:CCXI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202441968-61161
12/31/2023190-55-25-122
12/31/202264-140-94-522
6/30/202237-133-59-53N/A
3/31/202227-141-54-45N/A
12/31/202132-132-95-76N/A
9/30/202134-121-112-84N/A
6/30/202122-123-102-75N/A
3/31/202169-63-101-75N/A
12/31/202065-55-97-81N/A
9/30/202071-41-89-82N/A
6/30/202076-30-85-83N/A
3/31/202034-65-81-79N/A
12/31/201936-55-71-70N/A
9/30/201935-51-66-65N/A
6/30/201934-49-66-66N/A
3/31/201942-40-44-43N/A
12/31/201843-381616N/A
9/30/201890123638N/A
6/30/201890174142N/A
3/31/201884141920N/A
12/31/2017821845N/A
9/30/201731-29-10-10N/A
6/30/201726-30-5-5N/A
3/31/201720-317676N/A
12/31/201612-403939N/A
9/30/20167-443839N/A
6/30/20163-483838N/A
3/31/2016N/A-51N/A-41N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CCXI sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2%).

Beneficios vs. Mercado: Se prevé que CCXI sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que CCXI sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (85.1% al año) de CCXI crezcan más rápidamente que los del mercado US (11.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (85.1% al año) de CCXI crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CCXI sea baja dentro de 3 años (6.6%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2022/10/23 21:02
Precio de las acciones al final del día2022/10/19 00:00
Beneficios2022/06/30
Ingresos anuales2021/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

ChemoCentryx, Inc. está cubierta por 15 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Madhu KumarB. Riley Securities, Inc.
Harshita PolishettyB. Riley Securities, Inc.
Dae Gon HaBTIG